UNSPSC 51392223: Indanazoline hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H15N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z364A90IV8, chemically known as 2-imidazoline, 2-(4-indanylamino)-, hydrochloride but more generally known as indanazoline hydrochloride, which bears US NIH Compound Identifier 162014. European Medicines Agency schedules Indanazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02661MIG.

Most nations, for tariff and trade purposes, schedule indanazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, INDANAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Indanazoline hydrochloride bears US NLM identifiers UMLS ID C1609361 and NCI Concept Code C97700. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCC2.CL.

UNSPSC 51392223 Indanazoline hydrochloride is a Commodity code. The code appears to identify a specific pharmaceutical active ingredient, but the recent state and local procurement activity under this code does not reflect purchases of indanazoline hydrochloride itself. Instead, Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, solicits naloxone (an opioid antagonist used in overdose reversal) and safe drug deactivation systems—products with distinct therapeutic and operational purposes that fall outside the indanazoline hydrochloride scope. This mismatch suggests either a misclassification in the county's tagging or a data error in the UNSPSC assignment, as the actual procurement addresses public health emergency response and controlled-substance disposal rather than ophthalmic or vasoconstrictor pharmaceutical supply.

The sole recent opportunity identified under this code originates from a single county health department in central Florida. Seminole County's procurement requires quarterly deliveries of 1,900 units of naloxone and 800 safe drug deactivation systems annually to the Seminole County Community Health Building in Sanford, with a July 26, 2023 response deadline (note: the posted date of June 30, 2026 conflicts with the due date of July 26, 2023, suggesting a data entry error in the source). The contract runs two years with a one-year renewal option, requires E-Verify compliance and drug-free workplace certification, and is potentially FEMA-funded with corresponding federal regulatory requirements. The code shows minimal recent state and local activity, and the single opportunity identified does not align with the pharmaceutical ingredient the code nominally describes, limiting its utility for business development professionals pursuing indanazoline hydrochloride supply or related pharmaceutical contracting.